For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 214,712 | |||
| General and administrative | 70,883 | |||
| Total operating expenses | 285,595 | |||
| Loss from operations | -285,595 | |||
| Interest income, net | 30,030 | |||
| Total other income, net | 30,030 | |||
| Net loss before taxes | -255,565 | |||
| Provision for income taxes | 278 | |||
| Net loss after taxes | -255,843 | |||
| Basic EPS | -4.22 | |||
| Diluted EPS | -4.22 | |||
| Basic Average Shares | 60,690,820 | |||
| Diluted Average Shares | 60,690,820 | |||
Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics, Inc. (APGE)